AzTrials
AzTrials

Protein Metabolism DisorderCANOLAANCT06058403

Impact of Canola Protein Processing on Plasma Amino Acid Responses

A study testing 20g whey protein drink ingestion, 20g native canola protein drink ingestion and 20g processed canola protein #1 drink ingestion in people with Protein Metabolism Disorder, run by Maastricht University Medical Center at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein through the diet, the body is provided with enough amino acids to facilitate muscle protein building. Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
Conditions the study is for
Protein Metabolism Disorder
What is being tested?
20g whey protein drink ingestion, 20g native canola protein drink ingestion and 20g processed canola protein #1 drink ingestion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteNetherlands
Study dates
3 Oct 2023to 27 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Female sex
  • Aged between 18 and 35 y inclusive
  • BMI between 18.5 and 30 kg/m2

Who cannot join

  • Intolerant to milk lactose
  • Allergic to milk protein / products
  • Mustard allergy
  • Vegan lifestyle
  • Participating in a structured (progressive) exercise program
  • Smoking regularly
Show all 16Show fewer
  • Diagnosed GI tract disorders or diseases
  • Diagnosed musculoskeletal disorders
  • Diagnosed metabolic disorders (e.g., diabetes)
  • Hypertension (blood pressure above 140/90 mmHg)
  • Donated blood 2 months prior to test day
  • Pregnant
  • Using third generation oral contraceptives
  • Use of any medications known to affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories).
  • Chronic use of gastric acid suppressing medication as this impairs protein digestion (i.e., proton pump inhibitors, H2-antagonists)
  • People with Phenylketonuria

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Maastricht University Medical Centre+

    Maastricht, Limburg, 6229ER

Other trials in Netherlands

About this study

Official title: The Impact of Canola Protein Processing on Postprandial Plasma Amino Acid Responses in Vivo in Young Females

Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein through the diet, the body is provided with enough amino acids to facilitate muscle protein building. Providing the growing world population with sufficient animal-derived protein is a challenge. Plant proteins can be produced on a more sustainable commercial scale than conventional animal-derived proteins and therefore can contribute to feeding our future population. Canola protein is a protein that is derived from rapeseed. The composition of canola seems to be comparable to that of other high-quality animal based protein sources. However, the collection of canola protein from rapeseed occurs in a special way. These treatment processes might affect canola protein digestion. The goal of this study is to investigate the most optimal way of canola protein processing on blood plasma amino acid responses.

Primary objective: To assess the impact of canola protein processing on 5h postprandial plasma total amino acid incremental area under the curve (iAUC) in vivo in healthy young females.

Hypothesis: it is hypothesized that the ingestion of 20g processed canola will result in greater 5h postprandial plasma total amino acid iAUC in vivo in healthy young females, when compared to the ingestion of 20g native canola protein isolate.

Read the detailed description

To assess whether volunteers are eligible to participate in this study, the investigator will invite them to the University for a screening. At the start of the screening session, the entire experimental trial will be explained, and any potential questions will be answered. Thereafter, the volunteers are asked to read, fill out, and sign the informed consent form. After signing the informed consent form, the participant's eligibility will be assessed based on the in- and exclusion criteria. To further asses their eligibility, participants will be asked to fill out a medical questionnaire to assess their general health, use of medication, habitual food intake, and physical activity. Next, blood pressure will be assessed. Body mass (with accuracy of 0.1 kg) and height (with accuracy of 0.01 m) will be determined. The screening sessions will take place in the morning and participants are instructed to not have any breakfast in the morning in order to avoid perturbations in body weight and possibly in the DEXA scan. In the event of an unexpected medical finding during the screening, subjects will always be notified. If a subject does not want to receive this notification, she cannot participate in the study. When the screening is successfully performed, the test days will be scheduled. Protein and amino acid metabolism in women can be influenced by the menstrual cycle. Therefore, the experimental test days will be standardized in a specific period of the menstrual cycle. The test days will be planned in the first 10 days after the start of the menses (day 1 of the follicular phase), when hormones levels (i.e., estrogen) are low. In practice, this means that the test days will be planned based on the subjects' menstrual cycle. Therefore, 2 test days can be performed within 1 menstrual cycle (allowing 2 days between test days for standardization) and further test days will be planned approximately 28 days thereafter. This allows the investigators to finish testing for a single participant within a relatively short time frame while still taking the menstrual cycle and accompanying hormonal influences into consideration. A similar approach was used in our lab in previous studies that included young healthy women (METC17-3-047 \& METC19-087). Throughout the study period, participants will also undergo a fasted Dual Energy X-ray Absorptiometry (DEXA) scan to assess body composition. A DEXA scan is a simple, non-invasive procedure. At the beginning of the procedure, subjects will be asked to lie down on a scanning table wearing underwear and they need to remain motionless during the measurements. As the scanner moves, a dual energy beam passes through the targeted skeletal muscle section and is measured by a detector. This procedure takes approximately 3 minutes. The DEXA-scan provides valuable insight in participants' body composition, with minimal radiation burden.

When the screening is successfully performed, the test day will be scheduled. In order to prevent major impact from the menstrual cycle on the measurements of protein metabolism, the test day will be scheduled to take place in the first 10 days of the follicular phase.

Each subject will participate in 4 experimental test days lasting ~5h. Subjects will be instructed to arrive at the university at 8:45 AM in an overnight fasted and rested state, meaning that participants are not allowed to eat and drink (except for water) from 22:00 the night prior to the experimental trial. They will be instructed to come to the university by car or public transportation. After the subjects arrive at the University, subjects will rest in a seated position and a Teflon catheter will be inserted in a heated dorsal hand vein and placed in a hot-box (60°C) for arterialized blood sampling. A baseline blood sample (Serum + plasma = 20 mL) will be collected at t=0 min to determine the amino acid concentrations prior to the intervention.

Then, subjects will ingest the assigned drink (20g native canola protein, 20g processed canola protein #1, 20g processed canola protein #2, or 20g whey protein). Subjects will be instructed to consume the drink within ~5 min. Upon drink ingestion, the stopwatch will be started (t= 0 min), and arterialized blood samples (10mL) will be collected at t = 15, 30, 45, 60, 90, 120, 180, 240, and 300 min. During the entire experimental test day, the hand with the dorsal hand catheter will be pre-heated for 10 minutes prior to every blood draw in a hot box at 60°C to increase blood flow. This makes it easier to collect blood and minimizes nutrient exchange from blood into other tissues. Therefore, it allows the investigators to collect nutrient-rich (arterialized) blood from a vein.

In total 10 times blood samples will be taken during the test day, the first sample that will be collected will be 20mL and subsequent samples will be 10mL, making a total of 110mL.

Additionally, gastro-intestinal (GI) symptoms will be assessed at t = 0, 30, and 180 minutes and palatability at t = 15 min by questionnaires.

Being tested
20g whey protein drink ingestion, 20g native canola protein drink ingestion, 20g processed canola protein #1 drink ingestion, 20g processed canola protein #2 drink ingestion
Keywords
Dietary protein, Plant protein, Protein processing, Protein digestion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 20g whey protein drink ingestionDietary supplement

    Also called Supplement

    Ingestion of a 300 mL drink containing 20g whey protein

  • 20g native canola protein drink ingestionDietary supplement

    Also called Supplement

    Ingestion of a 300 mL drink containing 20g native canola protein

  • 20g processed canola protein #1 drink ingestionDietary supplement

    Also called Supplement

    Ingestion of a 300 mL drink containing 20g processed canola protein #1

  • 20g processed canola protein #2 drink ingestionDietary supplement

    Also called Supplement

    Ingestion of a 300 mL drink containing 20g processed canola protein #2

Study groups in NCT06058403
Study groupRoleWhat they receive
Native canola proteinExperimental20g of canola protein
Receives: Dietary Supplement: 20g native canola protein drink ingestion
Processed canola protein #1Experimental20g of processed canola #1
Receives: Dietary Supplement: 20g processed canola protein #1 drink ingestion
Processed canola protein #2Experimental20g of processed canola #2
Receives: Dietary Supplement: 20g processed canola protein #2 drink ingestion
Whey proteinActive comparator20g of whey protein
Receives: Dietary Supplement: 20g whey protein drink ingestion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total amino acid availability

    The total amino acid availability is expressed as the incremental area under the curve (iAUC)

    Measured: 0 - 5 hours after drink ingestion

Secondary outcomes (7)
  1. Postprandial plasma total amino acid concentrations

    The total plasma amino acid concentrations from the sum of the individual amino acids

    Measured: 0 - 5 hours after drink ingestion

  2. Postprandial plasma individual amino acid concentrations

    The plasma amino acid concentrations of the individual amino acids

    Measured: 0 - 5 hours after drink ingestion

  3. Peak plasma amino acid concentrations

    The maximal plasma amino acid concentrations

    Measured: 0 - 5 hours after drink ingestion

  4. Time to peak plasma amino acid concentrations

    The time to reach maximal plasma amino acid concentrations

    Measured: 0 - 5 hours after drink ingestion

  5. iAUC essential amino acids concentrations

    Essential amino acid availability expressed as incremental area under the curve (iAUC)

    Measured: 0 - 5 hours after drink ingestion

  6. iAUC non-essential amino acid concentrations

    non-essential amino acid availability expressed as incremental area under the curve (iAUC)

    Measured: 0 - 5 hours after drink ingestion

  7. Plasma insulin concentrations

    Postprandial plasma insulin concentrations

    Measured: 0 - 5 hours after drink ingestion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2023
  2. Study start3 Oct 2023
  3. Primary completion27 May 2024
  4. Study completion27 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
Randomized, controlled, double-blind, cross-over intervention trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06058403
Sponsor's protocol ID
NL83369.068.23 / METC 23-025
Acronym
CANOLAA
Status last verified
Oct 2023
First submitted
5 Sep 2023
Last updated
30 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Boot N, Hermans WJH, Warnke I, Overman A, van Kranenburg JMX, Senden JM, Verdijk LB, van Loon LJC. Evaluation of processing of canola protein isolate on postprandial plasma amino acid profiles in healthy, young females. Amino Acids. 2025 Oct 17;57(1):50. doi: 10.1007/s00726-025-03482-1.

    PubMed 41107640

Questions about this trial

What is this clinical trial studying?

A study testing 20g whey protein drink ingestion, 20g native canola protein drink ingestion and 20g processed canola protein #1 drink ingestion in people with Protein Metabolism Disorder, run by Maastricht University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total amino acid availability (time frame: 0 - 5 hours after drink ingestion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06058403, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in